DISEASE CHARACTERISTICS:

• Diagnosis of 1 of the following:

  • Hodgkin's lymphoma or non-Hodgkin's lymphoma, meeting 1 of the following criteria:

    • Refractory to primary treatment regimen
    • Refractory to or relapse after salvage regimen

  • Acute myelogenous leukemia

    • Prior bone marrow relapse in second or later complete remission (CR)

  • Acute lymphoblastic leukemia, meeting 1 of the following criteria:

    • Prior bone marrow relapse in second or later CR
    • First CR and Philadelphia chromosome (Ph) positive or prior induction failure

  • Acute hybrid leukemia including mixed lineage, biphenotypic, and undifferentiated, meeting 1 of the following criteria:

    • Prior bone marrow relapse in second or later CR
    • First CR and Ph positive or prior induction failure

  • Myelodysplastic syndromes

    • Less than 10% blasts in bone marrow and blood
    • Refractory anemia (RA) and RA with ringed sideroblasts not eligible
    • Must be Fanconi's anemia negative

  • Chronic myelogenous leukemia, meeting 1 of the following criteria:

    • Chronic phase
    • Accelerated phase with less than 10% blasts in bone marrow and blood

  • Juvenile myelomonocytic leukemia

    • Less than 10% blasts in bone marrow and blood

• No active CNS malignancy

  • No tumor mass by CT scan for patients with lymphoma
  • No CNS 2 or 3 classification for patients with leukemia
  • No leptomeningeal disease
  • Prior CNS involvement allowed if no current evidence of CNS malignancy

• Donor criteria:

  • 5 or 6 antigen HLA-matched first-degree related donor

    • Single HLA-A or B locus mismatch allowed
  • Weight more than 15 kilograms

PATIENT CHARACTERISTICS:

Age:

• 4 to 21

Performance status:

• ECOG 0-2

Life expectancy:

• More than 3 months

Hematopoietic:

• See Disease Characteristics

Hepatic:

• Bilirubin < 2.0 mg/dL
• ALT/AST ≤ 2.5 times upper limit of normal (elevations due to malignancy may be allowed at the discretion of the principal investigator)
• No active hepatitis B
• No active hepatitis C

Renal:

• Creatinine normal for age OR
• Creatinine clearance ≥ 60 mL/min

Cardiovascular:

• LVEF ≥ 45% by MUGA OR
• Shortening fraction ≥ 28% by echocardiogram

Pulmonary:

• DLCO ≥ 50% of predicted

Other:

• No high risk of inability to comply with protocol
• Not pregnant or nursing
• Negative pregnancy test
• Fertile patients must use effective contraception
• HIV negative

PRIOR CONCURRENT THERAPY:

Biologic therapy:

• Prior autologous bone marrow transplantation allowed
• At least 100 days since prior allogeneic bone marrow transplantation with no ongoing active graft-vs-host disease

Chemotherapy:

• Prior chemotherapy to achieve criteria for Disease Characteristics allowed
• Concurrent intrathecal chemotherapy for CNS leukemia or CNS lymphoma allowed

Endocrine therapy:

• Not specified

Radiotherapy:

• Concurrent radiotherapy for testicular leukemia, CNS leukemia, or CNS lymphoma allowed

Surgery:

• Not specified

Other:

• Other concurrent therapy or prophylaxis for testicular leukemia or CNS lymphoma allowed